RSS Alerts

Share

More services

Related Links

  • Merck
  • Elsevier Ltd is not responsible for the content of external websites.

Related Stories

  • Drug Information Association (DIA) names new worldwide executive director
    The Drug Information Association (DIA) has announced the hiring of Paul Pomerantz, MBA, CAE, as its new worldwide executive director.
  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Cancer Research Technology and Cancer Research UK establish lipid metabolism research team
    Cancer Research Technology (CRT), Cancer Research UK’s commercial arm, has established a group of scientists with expertise in lipid metabolism – getting energy from fats and making building blocks for cell growth – to develop targets for potential new cancer drugs.
  • Catching up on Circulating Tumor Cell Technology
    Circulating tumor cells (CTCs) are cells that ‘escape’ from primary tumor cells and migrate into the bloodstream, where they circulate through the body. CTCs were first identified in the 1980s as cells that had the morphology of tumor cells but were found in the blood. Over the past two decades technological innovations have eased the detection and analysis of CTCs. The resulting investigations of CTCs are an important area of clinical research because they are demonstrating that CTCs have potential clinical value as warning signals of cancer progression.
  • Clinical candidate from PKB/AKT collaboration with Astex selected by AstraZeneca
    Astex Therapeutics announced recently that AstraZeneca has selected a clinical candidate from the PKB inhibitor collaborative programme.

Top 5 Stories

News

Merck appoints Dr Michael Rosenblatt as Executive Vice President and Chief Medical Officer

23 December 2009

Merck & Co. recently announced the appointment of Dr Michael Rosenblatt as Executive Vice President and Chief Medical Officer. Dr Rosenblatt will be Merck's primary voice to the global medical community.

Dr Rosenblatt will be responsible for bringing a greater focus to Merck’s medical activities worldwide and for shaping medical strategies. Dr Rosenblatt will report directly to Richard T. Clark (Merck’s chairman, president and CEO), will serve on the company’s Executive Committee and will lead the company's Global Center for Scientific Affairs.

‘Merck's fundamental mission is ensuring the well-being of patients worldwide and Dr Rosenblatt’s appointment reinforces our steadfast commitment to always remain focused on this goal,’ said Mr Clark. ‘Dr Rosenblatt's achievements in academia, clinical medicine and private industry are exceptional. With his nearly three decades of invaluable experience, I am pleased to welcome Dr Rosenblatt to Merck’s executive team.’

Dr Rosenblatt said, ‘Merck has built a great foundation on scientific innovation and dedication to the well-being of patients around the world and put an amazing team of researchers and scientists in place to drive the next wave of innovative products and services that save and improve lives. I look forward to working with my colleagues to make a difference in the lives of people around the world.’

Dr Rosenblatt has served as Dean of Tufts University School of Medicine since 2003. Before working at Tufts University, Dr Rosenblatt held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999–2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and BIDMC and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC.

Before that, Dr Rosenblatt served as Director of the Harvard-MIT Division of Health Sciences and Technology. Earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In leading most of Merck's international research efforts, he established two major basic research institutes. He also headed Merck Research's worldwide University and Industry Relations Department.

Dr Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone, the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck.

 

This article is featured in:
Companies and People

 

Comment on this article

You must be registered and logged in to leave a comment about this article.

Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water